| Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial NB Haas, J Manola, RG Uzzo, KT Flaherty, CG Wood, C Kane, M Jewett, ... The Lancet 387 (10032), 2008-2016, 2016 | 702 | 2016 |
| Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma TK Choueiri, P Tomczak, SH Park, B Venugopal, T Ferguson, YH Chang, ... New England Journal of Medicine 385 (8), 683-694, 2021 | 651 | 2021 |
| Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation JV Lee, A Carrer, S Shah, NW Snyder, S Wei, S Venneti, AJ Worth, ... Cell metabolism 20 (2), 306-319, 2014 | 594 | 2014 |
| Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial DC Smith, MR Smith, C Sweeney, AA Elfiky, C Logothetis, PG Corn, ... Journal of clinical oncology 31 (4), 412-419, 2013 | 533 | 2013 |
| Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology RJ Motzer, E Jonasch, N Agarwal, A Alva, M Baine, K Beckermann, ... Journal of the National Comprehensive Cancer Network 20 (1), 71-90, 2022 | 524 | 2022 |
| Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma TK Choueiri, U Vaishampayan, JE Rosenberg, TF Logan, AL Harzstark, ... Journal of Clinical Oncology 31 (2), 181-186, 2013 | 509 | 2013 |
| Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma RJ Motzer, NB Haas, F Donskov, M Gross-Goupil, S Varlamov, ... Journal of Clinical Oncology 35 (35), 3916-3923, 2017 | 407 | 2017 |
| Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti–epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer EK Rowinsky, GH Schwartz, JA Gollob, JA Thompson, NJ Vogelzang, ... Journal of clinical oncology 22 (15), 3003-3015, 2004 | 403 | 2004 |
| Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study AR Hansen, C Massard, PA Ott, NB Haas, JS Lopez, S Ejadi, ... Annals of oncology 29 (8), 1807-1813, 2018 | 361 | 2018 |
| Radiation and immunotherapy: a synergistic combination A Kalbasi, CH June, N Haas, N Vapiwala The Journal of clinical investigation 123 (7), 2756-2763, 2013 | 344 | 2013 |
| Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. GR Hudes, F Nathan, C Khater, N Haas, M Cornfield, B Giantonio, ... Journal of clinical oncology 15 (9), 3156-3163, 1997 | 344 | 1997 |
| PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial V Narayan, JS Barber-Rotenberg, IY Jung, SF Lacey, AJ Rech, MM Davis, ... Nature medicine 28 (4), 724-734, 2022 | 318 | 2022 |
| Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised … T Powles, P Tomczak, SH Park, B Venugopal, T Ferguson, ... The lancet oncology 23 (9), 1133-1144, 2022 | 233 | 2022 |
| NCCN guidelines insights: kidney cancer, version 1.2021: featured updates to the NCCN guidelines RJ Motzer, E Jonasch, S Boyle, MI Carlo, B Manley, N Agarwal, A Alva, ... Journal of the National Comprehensive Cancer Network 18 (9), 1160-1170, 2020 | 231 | 2020 |
| Hereditary kidney cancer syndromes NB Haas, KL Nathanson Advances in chronic kidney disease 21 (1), 81-90, 2014 | 230 | 2014 |
| NCCN guidelines insights: kidney cancer, version 2.2020: featured updates to the NCCN guidelines RJ Motzer, E Jonasch, MD Michaelson, L Nandagopal, JL Gore, S George, ... Journal of the National Comprehensive Cancer Network 17 (11), 1278-1285, 2019 | 226 | 2019 |
| Adjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trial NB Haas, J Manola, JP Dutcher, KT Flaherty, RG Uzzo, MB Atkins, ... JAMA oncology 3 (9), 1249-1252, 2017 | 198 | 2017 |
| Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors SA Piha-Paul, CL Hann, CA French, S Cousin, I Braña, PA Cassier, ... JNCI Cancer Spectrum 4 (2), pkz093, 2020 | 195 | 2020 |
| Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of … CL Slingluff Jr, GR Petroni, WC Olson, ME Smolkin, MI Ross, NB Haas, ... Clinical Cancer Research 15 (22), 7036-7044, 2009 | 173 | 2009 |
| Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study NM Chanzá, W Xie, MA Bilen, H Dzimitrowicz, J Burkart, DM Geynisman, ... The lancet oncology 20 (4), 581-590, 2019 | 164 | 2019 |
